GLP1R and chronic kidney disease: Another study focusing on SGLT-2 inhibitors and GLP-1 analogues prescription in T2DM-CKD noted that 12% and 10% of these patients are taking SGLT-2 inhibitors and GLP-1 analogues, respectively [39].